EGFR and head and neck squamous cell carcinoma: Until the introduction of immunotherapy agents, the only new agent that had been FDA approved for HNSCC in the USA was cetuximab, a monoclonal antibody (mAb) targeting epidermal growth factor receptor (EGFR).